Fig. 1A



Phospho-HER3
Inhibition (%)
0
10
20
30
40
50
60
70
80
90
100
110
0.1µg/ml
1µg/ml
Control
Mab205.10.2
U1-07
U1-53
U1-59
MM-Ab#6

Fig. 1B



Phospho-HER3
Inhibition (%)
110
100
90
80
70
60
50
40
30
20
10
0
0.1µg/ml
1µg/ml
Control
Mab205.10.2
8B8.2D9
1B4C3
2D1D12

Fig. 1C



Phospho-HER3
0.1µg/ml
1µg/ml
Inhibition (%)
110
100
90
80
70
60
50
40
30
20
10
0
Control
205
105.5
1B4C3
2D1D12
8B8.2D9

Fig. 2



Tumor volume [mm³] Median and IQR
2400
2100
1800
1500
1200
900
600
300
0
13
15
17
19
21
23
25
27
29
31
33
35
Time after cell inoculation [days]
Vehicle
Mab 205 10mg/kg q7dx3 i.p.

Fig. 3



Tumor volume [mm³] Median and IQR
500
450
400
350
300
250
200
150
100
50
0
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
Time after fragment transplantation [Day]
Vehicle
Mab 205 10mg/kg q7d i.p.

Fig. 4



Tumor volume [mm³] Median and IQR
900
800
700
600
500
400
300
200
100
0
25
28
31
34
37
40
43
46
49
52
55
58
Time after fragment transplantation [Day]
vehicle
Mab 205 25mg/kg i.p.

Fig. 5



Vehicle
Mab205.10.2
10mg/kg; i.p. q7d
pertuzumab
30mg/kg LD i.p.
15mg/kg MD i.p. q7d
Mab 205.10.2
10mg/kg; i.p. q7d pertuzumab
30mg/kg LD i.p.
15mg/kg MD i.p. q7d
Tumor Volume [mm³]; Mean
0
100
200
300
400
500
600
700
30
35
40
45
50
55
60
65
70
75
80
85
Days after cell inoculation [d]

Fig. 6




A
Vehicle
RG7116 0.1 mg/kg
RG7116 0.3 mg/kg
RG7116 1.0 mg/kg
RG7116 3.0 mg/kg
RG7116 10 mg/kg
RG7116 25 mg/kg
Tumor volume (mm³), median ± IQR
Time after innoculation (Day)
B
Vehicle
RG7116 25 mg/kg
RG7116 10 mg/kg
RG7116 3 mg/kg
RG7116 1 mg/kg
RG7116 0.3 mg/kg
RG7116 0.1 mg/kg
MM-IgG1 25 mg/kg
HER3
pHER3
C
Vehicle control
RG7116 0,1mg/kg
RG7116 10mg/kg

Fig. 7


A
Tumor growth inhibition (%)
100
80
60
40
20
0
Lu7177
Lu7860
LXFE722
Lu7414
QG56
LXFE646
LXFA1584
NCI-H322M
LXFA586
A549
NCI-H1975
LXFA983
HCC827
Lu7387
Lu7462
NCI-H441
B
Tumor volume (mm³), median ± IQR
1000
800
600
400
200
0
Vehicle
RG7116
58 61 64 67 70 73 76 79 82 85 88 91 94 97
Time after fragment transplantation (day)
C
Tumor volume (mm³), median ± IQR
1000
10
Vehicle
GA201
RG7116
RG7116 + GA201
15 20 25 30 35 40 45 50 55
Study day
D
Tumor volume (mm³), median ± IQR
300
30
Vehicle
Pertuzumab
RG7116
RG7116 + pertuzumab
60 64 68 72 76 80 84 88 92
Study day